Skip to main content

Research Repository

Advanced Search

Projects (482)

Patient acceptability to a novel prosthetic device: A randomised feasibility study in older patients with vascular-related amputations and multimorbidities

Patient acceptability to a novel prosthetic device: A randomised feasibility study in older patients with vascular-related amputations and multimorbidities Apr 1, 2018 - Jun 30, 2023
Background: Almost 6,000 people have a leg amputated in the UK annually. These are mostly patients over 50 years and usually with diabetes and/or blood vessel problems. Older patients are often prescribed standard ankle-foot prostheses, unlike those... Read More about Patient acceptability to a novel prosthetic device: A randomised feasibility study in older patients with vascular-related amputations and multimorbidities.

PIONEER5: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment Nov 1, 2016 - Oct 31, 2019
Primary objective:
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus placebo, both in combination with metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal insulin on glycaemic control i... Read More about PIONEER5: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.

Victoria: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Centre Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerlCiguaT Gloobal Study in Subjects With Heart Failure With Reduced Ejection Fraction Jan 11, 2017 - Jan 31, 2022
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven trial of MK-1242 (vericiguat) in subjects with heart failure with reduced ejection
fraction (HFrEF).
Approximately 4872 subjects will be randomized g... Read More about Victoria: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Centre Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerlCiguaT Gloobal Study in Subjects With Heart Failure With Reduced Ejection Fraction.

Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Aug 31, 2022
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.... Read More about Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.

IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial May 5, 2017 - Aug 31, 2022
A BHF funded study to compare the effect of additional intravenous iron IV therapy versus standard therapy for patients with chronic heart failure and left ventricular systolic dysfunction and iron deficiency.
Recruitment is 12 patients per year - w... Read More about IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial.

AX-8 Clinical Research Collaboration Jun 1, 2016 - May 31, 2018
Primary:
Study the efficacy of compound AX-8 in suppressing cough and upper airway symptoms in subjects with cough hypersensitivity syndrome.

Secondary:
Study the safety of compound AX-8.

TRANSFORM: Reducing Inequalities in Cancer Outcomes in Yorkshire: Realising our potential for innovation in Diagnosis, Patient Management, Survivorship and Palliative Care Research Sep 1, 2017 - Dec 31, 2026
The death rate is higher in Yorkshire than the rest of England resulting in about 200 extra deaths each year of which more than half are in Hull. There are other significant cancer outcome inequalities between different groups; for example poorer pe... Read More about TRANSFORM: Reducing Inequalities in Cancer Outcomes in Yorkshire: Realising our potential for innovation in Diagnosis, Patient Management, Survivorship and Palliative Care Research.

PEOPLE: Primary care and community Engagement to Optimise time to Presentation with Lung cancEr symptoms in HULL Jun 1, 2017 - Jun 30, 2023
More people are diagnosed with and die from lung cancer in Hull than any other place in Yorkshire. Our aim is to improve earlier diagnosis of lung cancer by [1] getting people to see their doctor if they get lung symptoms and [2] getting GPs to refe... Read More about PEOPLE: Primary care and community Engagement to Optimise time to Presentation with Lung cancEr symptoms in HULL.

The role of bacteria in the skin: Cold atmospheric plasma for the treatment of pathological skin healing Apr 1, 2017 - Mar 31, 2020
Chronic wounds remain a major area of unmet clinical need, with infection a principle contributing factor to wound chronicity. This project builds upon strong preliminary data suggesting that healing outcome can be directly linked to both wound micro... Read More about The role of bacteria in the skin: Cold atmospheric plasma for the treatment of pathological skin healing.

An introduction to Total Sweet Xylitol Sep 1, 2019 - Aug 31, 2020
Purpose of the current project is to;

1) Determine the impact of Xylitol on weekly calorific intake
2) Access subjective satiation levels
3) Explore the relationship between gut hormone response and Xylitol consumption.